Hemorrhage and thrombosis in COVID‑19‑patients supported with extracorporeal membrane oxygenation

Written By CCRG

An international study based on the COVID‑19 critical care consortium

Maximilian Feth, Natasha Weaver, Robert B. Fanning, Sung‑Min Cho, Matthew J. Griffee, Mauro Panigada, Akram M. Zaaqoq, Ahmed Labib, Glenn J. R. Whitman, Rakesh C. Arora, Bo S. Kim, Nicole White, Jacky Y. Suen, Gianluigi Li Bassi, Giles J. Peek, Roberto Lorusso, Heidi Dalton, John F. Fraser and Jonathon P. Fanning on behalf of the COVID‑19 Critical Care Consortium J Intensive Care. DOI 10.1186/s40560-024-00726-2

Background: Extracorporeal membrane oxygenation (ECMO) is a rescue therapy in patients with severe acute respiratory distress syndrome (ARDS) secondary to COVID-19. While bleeding and thrombosis complicate ECMO, these events may also occur secondary to COVID-19. Data regarding bleeding and thrombotic events in COVID-19 patients on ECMO are sparse.

CCRG
Previous

The Impact of Acute Exercise on Hemostasis and Angiogenesis Mediators in Patients With Continuous-Flow Left Ventricular Assist Devices
Next

Acid-sensing ion channel 1a blockade reduces myocardial injury in rodent models of myocardial infarction